Who
Adam M. Veness
SVP, General Counsel and Sec.
Company insider
Files Form 4 as: SVP, General Counsel and Sec., Dianthus Therapeutics; General Counsel, Cyteir Therapeutics; SVP, General Counsel and Sec., Acceleron Pharma.
In numbers
- Trades disclosed
- 75
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $11.7M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 5 Jun 2019
- Last trade
- 13 Aug 2026
- Last filed
- 14 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 14 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $273K15,000 at $18.17 | filing |
| 13 Aug 2026filed 14 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 13 Aug 2026filed 14 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $273K15,000 at $18.17 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,167 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $289K16,167 at $17.88 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M16,167 at $110.38 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,167 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $289K16,167 at $17.88 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.8M16,167 at $110.38 | filing |
| 7 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $69K3,833 at $17.88 | filing |
| 7 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $356K3,217 at $110.61 | filing |
| 7 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K616 at $111.18 | filing |
| 7 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,833 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,833 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $69K3,833 at $17.88 | filing |
| 7 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $356K3,217 at $110.61 | filing |
| 7 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $68K616 at $111.18 | filing |
| 17 Jun 2026filed 18 Jun 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $536K30,000 at $17.88 | filing |
| 17 Jun 2026filed 18 Jun 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.3M16,771 at $80.34 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)DNTH · tickerreport.com · 22 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Adam M. Veness; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.